abemaciclib + ramucirumab

Abemaciclib + ramucirumab is an investigational **combination therapy** consisting of abemaciclib, a small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), and ramucirumab, a recombinant human monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2). - **Mechanism of Action:** - Abemaciclib inhibits CDK4/6, leading to cell cycle arrest in the G1 phase and reduced proliferation of tumor cells. - Ramucirumab binds VEGFR-2, blocking VEGF signaling and thereby inhibiting angiogenesis, the process by which tumors create their own blood supply. - **Developer:** Abemaciclib is developed by Eli Lilly; ramucirumab is also developed by Eli Lilly. - **Primary Indication:** This combination is investigated for the treatment of **advanced or metastatic non-small cell lung cancer (NSCLC)** where single-agent activity has been demonstrated for both drugs and clinical trials have explored their combined safety and antitumor effect[1][3][4].